Trial Profile
A Phase II Trial of R115777 [tipifarnib] (NSC #702818) in Patients With Advanced Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 13 Jun 2012 Actual patient number is 62 according to ClinicalTrials.gov.
- 13 Jun 2012 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
- 13 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.